Despite low absolute risk, Pfizer/BioNTech BNT162b2 COVID-19First identified in 2019 in Wuhan, China, Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has spread globally, resulting in the 2019–20 coronavirus pandemic.”>COVID-19 vaccine associated with increased risk of carditis.
Markedly increased risk in adolescents after 2nd dose may warrant refined vaccination strategies
A case-control study found that despite low absolute risk, there is an increased relative risk of carditis associated with BNT162b2 (commonly-known as Pfizer/BioNTech vaccine) vaccination. Considering the markedly increased risk in adolescents after the second dose, vaccination strategies may need to continuously consider the risk and benefits for different sub-populations, rather than taking a ‘one-size-fits-all’ approach. The findings will be published today (January 24, 2022) in Annals of Internal Medicine.
Carditis is a rare inflammation of the heart often caused by bacterial, viral, and parasitic infections. Common subtypes of carditis include myocarditis, an inflammation of the heart muscle, and pericarditis, an inflammation of the outer lining of the heart. Case reports of carditis after BNT162b2 vaccination have accrued globally. Several studies have also reported similar findings, but analytic research on the speculative association is limited.
Researchers from the University of Hong Kong studied 160 case patients (with carditis) and 1,533 control patients (without carditis) to examine the potential risk of carditis associated with vaccination with BNT162b2 or CoronaVac. Ten control patients were matched with case patients based on age, sex, and date of hospital admission.
After conducting analyses, the authors found 20 cases of carditis associated with BNT162b2 and 7 associated with CoronaVac vaccination. Patients who received BNT162b2 were 3 times more likely to experience carditis than unvaccinated patients. On the other hand, patients who received CoronaVac had a similar chance as unvaccinated patients to experience carditis.
The authors also observed that risk increase associated with BNT162b2 was predominant in males and was more likely to be seen after the second dose.
Cumulative incidence of carditis after vaccination was 0.57 per 100,000 doses of BNT162b2 and 0.31 per 100,000 doses of CoronaVac, demonstrating a very low absolute risk of carditis after vaccination.
According to the authors, none of the 20 case patients with carditis after BNT162b2 vaccination were admitted to the ICU or died within the observation period, compared with 14 of 133 unvaccinated patients admitted to the ICU and 12 deaths.
Reference: 24 January 2022, Annals of Internal Medicine.